antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N avapro oral J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; avapro oral ISBN 0-9757919-2-3.

(INN) (pronounced /?rb??s?rt?n/) is an angiotensin II receptor antagonists, irbesartan avapro oral indicated for the treatment of hypertension. avapro oral was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 avapro oral See also[edit] Clinical useMain article: Angiotensin avapro oral receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, avapro oral avapro oral Rohde R, Raz avapro oral Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist.

CoAprovel, Karvezide, Avalide and Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, avapro oral T, Pohl MA, Lewis JB, Ritz Lewis.